Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5887)
All Articles published online
|
Jul 28, 2010 (publication date) through Nov 8, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: |
Kim JW, Lee KL, Jeong JB, Kim BG, Shin S, Kim JS, Jung HC, Song IS. Proton pump inhibitors as a risk factor for recurrence of |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v16/i28/3573.htm |
| Number | Citing Articles |
| 1 |
D. W. Eyre, A. S. Walker, D. Wyllie, K. E. Dingle, D. Griffiths, J. Finney, L. O'Connor, A. Vaughan, D. W. Crook, M. H. Wilcox, T. E. A. Peto. Predictors of First Recurrence of Clostridium difficile Infection: Implications for Initial Management. Clinical Infectious Diseases 2012; 55(suppl 2): S77 doi: 10.1093/cid/cis356
|
| 2 |
Yun Jeong Lim, Hoon Jai Chun. Recent Advances in NSAIDs-Induced Enteropathy Therapeutics: New Options, New Challenges. Gastroenterology Research and Practice 2013; 2013: 1 doi: 10.1155/2013/761060
|
| 3 |
Abhishek Deshpande, Chaitanya Pant, Vinay Pasupuleti, David D.K. Rolston, Anil Jain, Narayan Deshpande, Priyaleela Thota, Thomas J. Sferra, Adrian V. Hernandez. Association Between Proton Pump Inhibitor Therapy and Clostridium difficile Infection in a Meta-Analysis. Clinical Gastroenterology and Hepatology 2012; 10(3): 225 doi: 10.1016/j.cgh.2011.09.030
|
| 4 |
|
| 5 |
Christine S. Cocanour. Best Strategies in Recurrent or PersistentClostridium difficileInfection. Surgical Infections 2011; 12(3): 235 doi: 10.1089/sur.2010.080
|
| 6 |
Caoilfhionn OʼDonoghue, Lorraine Kyne. Update on Clostridium difficile infection. Current Opinion in Gastroenterology 2011; 27(1): 38 doi: 10.1097/MOG.0b013e3283411634
|
| 7 |
José Millán Oñate Gutiérrez, María Virginia Villegas, Adriana Correa. Prevalencia y factores relacionados con la infección por Clostridium difficile en un centro hospitalario de alta complejidad en Cali (Colombia). Infectio 2017; 21(1) doi: 10.22354/in.v21i1.646
|
| 8 |
|
| 9 |
Tammy A. Novotne, Hatem O. Kaseb. The changing face of Clostridium difficile in critical care. Nursing Critical Care 2013; 8(3): 26 doi: 10.1097/01.CCN.0000429383.25720.13
|
| 10 |
Marya D. Zilberberg, Andrew F. Shorr, Scott T. Micek, Marin H. Kollef. Clostridium difficile Recurrence Is a Strong Predictor of 30-Day Rehospitalization Among Patients in Intensive Care. Infection Control & Hospital Epidemiology 2015; 36(3): 273 doi: 10.1017/ice.2014.47
|
| 11 |
Tadayuki Oshima, Liping Wu, Min Li, Hirokazu Fukui, Jiro Watari, Hiroto Miwa. Magnitude and direction of the association between Clostridium difficile infection and proton pump inhibitors in adults and pediatric patients: a systematic review and meta-analysis. Journal of Gastroenterology 2018; 53(1): 84 doi: 10.1007/s00535-017-1369-3
|
| 12 |
Ernesto Martínez. Primera aparición de Clostridium difficile en la literatura científica colombiana. Infectio 2011; 15(4): 217 doi: 10.1016/S0123-9392(11)70734-2
|
| 13 |
|
| 14 |
Rosan Meyer, Yvan Vandenplas, Adriana Chebar Lozinsky, Mario C. Vieira, Roberto Berni Canani, Christophe Dupont, Pinar Uysal, Ozlem Cavkaytar, Rebecca Knibb, David M. Fleischer, Anna Nowak‐Wegrzyn, Carina Venter. Diagnosis and management of food allergy‐associated gastroesophageal reflux disease in young children—EAACI position paper. Pediatric Allergy and Immunology 2022; 33(10) doi: 10.1111/pai.13856
|
| 15 |
A. L. Safin, S. I. Achkasov, M. A. Sukhina, O. I. Sushkov. RISK FACTORS FOR DIARRHEA ASSOCIATED WITH CLOSTRIDIUM DIFFICILE, IN COLOPROCTOLOGICAL PATIENTS (review). Koloproktologia 2017; (1): 59 doi: 10.33878/2073-7556-2017-0-1-59-67
|
| 16 |
Gianni B. Scappaticci, Anthony J. Perissinotti, Jerod L. Nagel, Dale L. Bixby, Bernard L. Marini. Risk factors and impact of Clostridium difficile recurrence on haematology patients. Journal of Antimicrobial Chemotherapy 2017; 72(5): 1488 doi: 10.1093/jac/dkx005
|
| 17 |
Gene Y. Im, Rani J. Modayil, Cheng T. Lin, Steven J. Geier, Douglas S. Katz, Martin Feuerman, James H. Grendell. The Appendix May Protect Against Clostridium difficile Recurrence. Clinical Gastroenterology and Hepatology 2011; 9(12): 1072 doi: 10.1016/j.cgh.2011.06.006
|
| 18 |
Cindy Bourne, Bruno Charpiat, Nicolas Charhon, Camille Bertin, Aurore Gouraud, Christelle Mouchoux, Saadia Skalli, Audrey Janoly-Dumenil. Effets indésirables émergents des inhibiteurs de la pompe à protons. La Presse Médicale 2013; 42(2): e53 doi: 10.1016/j.lpm.2012.09.016
|
| 19 |
Vanessa Stevens, Ghinwa Dumyati, Jack Brown, Edwin van Wijngaarden. Differential risk of Clostridium difficile infection with proton pump inhibitor use by level of antibiotic exposure. Pharmacoepidemiology and Drug Safety 2011; 20(10): 1035 doi: 10.1002/pds.2198
|
| 20 |
Matthias G Hautmann, Matthias Hipp, Oliver Kölbl. Clostridium difficile-associated diarrhea in radiooncology: an underestimated problem for the feasibility of the radiooncological treatment?. Radiation Oncology 2011; 6(1) doi: 10.1186/1748-717X-6-89
|
| 21 |
C. Bavishi, H. L. DuPont. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Alimentary Pharmacology & Therapeutics 2011; 34(11-12): 1269 doi: 10.1111/j.1365-2036.2011.04874.x
|
| 22 |
Daniel E Freedberg, Julian A Abrams. Does Confounding Explain the Association Between PPIs and Clostridium difficile -Related Diarrhea?. American Journal of Gastroenterology 2013; 108(2): 278 doi: 10.1038/ajg.2012.395
|
| 23 |
Hee Kyoung Choi, Kye Hyung Kim, Sun Hee Lee, Su Jin Lee. Risk Factors for Recurrence ofClostridium difficileInfection: Effect of Vancomycin-resistant Enterococci Colonization. Journal of Korean Medical Science 2011; 26(7): 859 doi: 10.3346/jkms.2011.26.7.859
|
| 24 |
Megan Jaynes, Avinash B. Kumar. The risks of long-term use of proton pump inhibitors: a critical review. Therapeutic Advances in Drug Safety 2019; 10 doi: 10.1177/2042098618809927
|
| 25 |
Yuvarajgouda N. Patil, Sharanappa T. Nandibewoor. Development of novel Ce doped ZnO/graphene based sensor for electrochemical investigation of potassium-competitive acid blocker: Vonoprazan. Materials Science in Semiconductor Processing 2024; 171: 108039 doi: 10.1016/j.mssp.2023.108039
|
| 26 |
Brianna R. Murphy, Natalie J. Dailey Garnes, Hyunsoo Hwang, Christine B. Peterson, Kevin W. Garey, Pablo Okhuysen. Increased Prevalence of Clostridioides difficile Infection Among Pediatric Oncology Patients: Risk Factors for Infection and Complications. Pediatric Infectious Disease Journal 2024; 43(2): 136 doi: 10.1097/INF.0000000000004178
|
| 27 |
Wasef Na’amnih, Amos Adler, Tamar Miller-Roll, Dani Cohen, Yehuda Carmeli. Risk factors for recurrent Clostridium difficile infection in a tertiary hospital in Israel. European Journal of Clinical Microbiology & Infectious Diseases 2018; 37(7): 1281 doi: 10.1007/s10096-018-3247-1
|
| 28 |
Vanessa Arriola, Jessica Tischendorf, Jackson Musuuza, Anna Barker, Jeffrey W. Rozelle, Nasia Safdar. Assessing the Risk of Hospital-AcquiredClostridium DifficileInfection With Proton Pump Inhibitor Use: A Meta-Analysis. Infection Control & Hospital Epidemiology 2016; 37(12): 1408 doi: 10.1017/ice.2016.194
|
| 29 |
A.M. Jones, E.J. Kuijper, M.H. Wilcox. Clostridium difficile: A European perspective. Journal of Infection 2013; 66(2): 115 doi: 10.1016/j.jinf.2012.10.019
|
| 30 |
Konstantinos Z. Vardakas, Konstantinos A. Polyzos, Konstantina Patouni, Petros I. Rafailidis, George Samonis, Matthew E. Falagas. Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. International Journal of Antimicrobial Agents 2012; 40(1): 1 doi: 10.1016/j.ijantimicag.2012.01.004
|
| 31 |
Josmi Joseph, Shashideep Singhal, Gia M. Patel, Sury Anand. Clostridium Difficile Colitis. American Journal of Therapeutics 2014; 21(5): 385 doi: 10.1097/MJT.0b013e318245992d
|
| 32 |
T. P. Rakesh. Proton pump inhibitors: use, misuse and concerns about long-term therapy. Clinical Journal of Gastroenterology 2011; 4(2): 53 doi: 10.1007/s12328-011-0208-y
|
| 33 |
Andrea Lo Vecchio, George M. Zacur. Clostridium difficile infection. Current Opinion in Gastroenterology 2012; 28(1): 1 doi: 10.1097/MOG.0b013e32834bc9a9
|
| 34 |
Marya D Zilberberg, Kimberly Reske, Margaret Olsen, Yan Yan, Erik R Dubberke. Risk factors for recurrent Clostridium difficile infection (CDI) hospitalization among hospitalized patients with an initial CDI episode: a retrospective cohort study. BMC Infectious Diseases 2014; 14(1) doi: 10.1186/1471-2334-14-306
|
| 35 |
Sahil Khanna, Scott L. Aronson, Patricia P. Kammer, Larry M. Baddour, Darrell S. Pardi. Gastric Acid Suppression and Outcomes in Clostridium difficile Infection: A Population-Based Study. Mayo Clinic Proceedings 2012; 87(7): 636 doi: 10.1016/j.mayocp.2011.12.021
|
| 36 |
G. Braun, H. Messmann. Stressulkusprophylaxe. Der Gastroenterologe 2014; 9(6): 535 doi: 10.1007/s11377-014-0914-3
|
| 37 |
Kangni Chen, Stephanie d’Arc, Naveen Setty, Kathy Bamford, Neil Fairweather, Jonathan Tyrrell-Price. In Recurrent C. difficile, the CRP Response to the Primary C. difficile Infection Predicts Whether the Same Strain or a Different Strain will Cause a Second Infection. Digestive Diseases and Sciences 2013; 58(6): 1683 doi: 10.1007/s10620-012-2534-4
|
| 38 |
John P. Haran, Evan Bradley, Emily Howe, Xun Wu, Jennifer Tjia. Medication Exposure and Risk of Recurrent Clostridium difficile Infection in Community‐Dwelling Older People and Nursing Home Residents. Journal of the American Geriatrics Society 2018; 66(2): 333 doi: 10.1111/jgs.15176
|
| 39 |
Moacyr Silva Júnior. Recent changes in Clostridium difficile infection. Einstein (São Paulo) 2012; 10(1): 105 doi: 10.1590/S1679-45082012000100023
|
| 40 |
Charlie T Seto, Patricio Jeraldo, Robert Orenstein, Nicholas Chia, John K DiBaise. Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility. Microbiome 2014; 2(1) doi: 10.1186/2049-2618-2-42
|
| 41 |
Bekure B. Siraw, Arthur L. Reingold, Didien Meyahnwi. Association between epidemiologic case definition categories and adverse clinical outcome in patients with Clostridiodes difficile infection in San Francisco County, California: a five-year retrospective cohort study. BMC Infectious Diseases 2023; 23(1) doi: 10.1186/s12879-023-08030-4
|
| 42 |
Md.Mohaimenul Islam, Tahmina N. Poly, Bruno A. Walther, Navneet K. Dubey, Dina N. Anggraini Ningrum, Syed-Abdul Shabbir, Yu-Chuan (Jack) Li. Adverse outcomes of long-term use of proton pump inhibitors: a systematic review and meta-analysis. European Journal of Gastroenterology & Hepatology 2018; 30(12): 1395 doi: 10.1097/MEG.0000000000001198
|
| 43 |
Monica Viladomiu, Raquel Hontecillas, Lijuan Yuan, Pinyi Lu, Josep Bassaganya-Riera. Nutritional protective mechanisms against gut inflammation. The Journal of Nutritional Biochemistry 2013; 24(6): 929 doi: 10.1016/j.jnutbio.2013.01.006
|
| 44 |
Karn Wijarnpreecha, Suthanya Sornprom, Charat Thongprayoon, Parkpoom Phatharacharukul, Wisit Cheungpasitporn. Nasogastric tube and outcomes of Clostridium difficile infection: A systematic review and meta‐analysis. Journal of Evidence-Based Medicine 2018; 11(1): 40 doi: 10.1111/jebm.12288
|
| 45 |
Arthur Leibovitz, Alexandra Yarovoy, Nataly Sharshar, Zvi Buckman, Eliyahy Haim Mizrahi, Emily Lubart. Clostridium difficile-associated disease: A primary clinical evaluation of elderly patients in a geriatric hospital. American Journal of Infection Control 2016; 44(10): 1158 doi: 10.1016/j.ajic.2016.03.069
|
| 46 |
|
| 47 |
V. I. Simanenkov, S. V. Tikhonov. Rebamipide: New opportunities of gastroenteroprotection. Terapevticheskii arkhiv 2015; 87(12): 134 doi: 10.17116/terarkh20158712134-137
|
| 48 |
Anna Wentz Sams, Laurie Kennedy-Malone. Recognition and management of Clostridium difficile in older adults. The Nurse Practitioner 2017; 42(5): 50 doi: 10.1097/01.NPR.0000512254.47992.8e
|
| 49 |
Kentaro Oka, Takako Osaki, Tomoko Hanawa, Satoshi Kurata, Mitsuhiro Okazaki, Taki Manzoku, Motomichi Takahashi, Mamoru Tanaka, Haruhiko Taguchi, Takashi Watanabe, Takashi Inamatsu, Shigeru Kamiya. Molecular and Microbiological Characterization of Clostridium difficile Isolates from Single, Relapse, and Reinfection Cases. Journal of Clinical Microbiology 2012; 50(3): 915 doi: 10.1128/JCM.05588-11
|
| 50 |
Marya D. Zilberberg, Kimberly Reske, Margaret Olsen, Yan Yan, Erik R. Dubberke. Development and validation of a recurrent Clostridium difficile risk‐prediction model. Journal of Hospital Medicine 2014; 9(7): 418 doi: 10.1002/jhm.2189
|
| 51 |
Wesam Frandah, Jane Colmer-Hamood, Kenneth Nugent, Rishi Raj. Patterns of Use of Prophylaxis for Stress-Related Mucosal Disease in Patients Admitted to the Intensive Care Unit. Journal of Intensive Care Medicine 2014; 29(2): 96 doi: 10.1177/0885066612453542
|
| 52 |
Chun Shing Kwok, Aaron Kobina Arthur, Chukwudubem Ifeanyichukwu Anibueze, Sonal Singh, Rodrigo Cavallazzi, Yoon Kong Loke. Risk of Clostridium difficile Infection With Acid Suppressing Drugs and Antibiotics: Meta-Analysis. American Journal of Gastroenterology 2012; 107(7): 1011 doi: 10.1038/ajg.2012.108
|
| 53 |
Han Seung Ryu, Yong Sung Kim, Geom Seog Seo, Yu Min Lee, Suck Chei Choi. Risk Factors for RecurrentClostridium difficileInfection. Intestinal Research 2012; 10(2): 176 doi: 10.5217/ir.2012.10.2.176
|
| 54 |
Catherine Rioufol, Sébastien Lamy, Cécile Conte, Pauline Jeanneau, Giselle Compaci, Cyrille Delpierre, Maryse Lapeyre-Mestre, Guy Laurent, Fabien Despas. Non-cancer drug consumption during the early trajectory of lymphoma survivorship. Therapies 2018; 73(4): 307 doi: 10.1016/j.therap.2017.10.007
|
| 55 |
Tom C. Martinsen, Reidar Fossmark, Helge L. Waldum. The Phylogeny and Biological Function of Gastric Juice—Microbiological Consequences of Removing Gastric Acid. International Journal of Molecular Sciences 2019; 20(23): 6031 doi: 10.3390/ijms20236031
|
| 56 |
Abhishek Deshpande, Vinay Pasupuleti, Priyaleela Thota, Chaitanya Pant, David D.K. Rolston, Adrian V. Hernandez, Curtis J. Donskey, Thomas G. Fraser. Risk Factors for Recurrent Clostridium difficile Infection: A Systematic Review and Meta-Analysis. Infection Control & Hospital Epidemiology 2015; 36(4): 452 doi: 10.1017/ice.2014.88
|
| 57 |
Stephanie Jordan, Nathan Hui, Mark Doudle, Michael Von Papen, Arun Naik, Cu Tai Lu, Gregory Nolan, Michelle Cooper. Incidence of Clostridioides difficile in patients post loop ileostomy reversal in an Australian tertiary hospital: a retrospective study. ANZ Journal of Surgery 2022; 92(3): 403 doi: 10.1111/ans.17411
|
| 58 |
Swetha Ramanathan, Stuart Johnson, Stephen P. Burns, Stephen M. Kralovic, Barry Goldstein, Bridget Smith, Dale N. Gerding, Charlesnika T. Evans. Recurrence of Clostridium difficile infection among veterans with spinal cord injury and disorder. American Journal of Infection Control 2014; 42(2): 168 doi: 10.1016/j.ajic.2013.08.009
|
| 59 |
Elizabeth E Roughead, Esther W Chan, Nam-Kyong Choi, Jenna Griffiths, Xue-Mei Jin, Joongyub Lee, Michio Kimura, Tomomi Kimura, Kiyoshi Kubota, Edward Chia-Cheng Lai, Kenneth KC Man, Tuan Anh Nguyen, Nobuhiro Ooba, Byung-Joo Park, Tsugumichi Sato, Ju-Young Shin, TongTong Wang, Ian CK Wong, Yea-Huei Kao Yang, Nicole L Pratt. Proton pump inhibitors and risk ofClostridium difficileinfection: a multi-country study using sequence symmetry analysis. Expert Opinion on Drug Safety 2016; 15(12): 1589 doi: 10.1080/14740338.2016.1238071
|
| 60 |
Ji Won Kim. Risk Factors for Delayed Recurrence ofClostridium difficileInfection. Intestinal Research 2014; 12(4): 266 doi: 10.5217/ir.2014.12.4.266
|
| 61 |
Nicholas V. Parmar, Jonathan Glauser. Systematic Review of Current Treatment and Prevention Strategies for Clostridium difficile. Current Emergency and Hospital Medicine Reports 2019; 7(3): 66 doi: 10.1007/s40138-019-00186-1
|
| 62 |
John P. Haran, Doyle V. Ward, Shakti K. Bhattarai, Ethan Loew, Protiva Dutta, Amanda Higgins, Beth A. McCormick, Vanni Bucci. The high prevalence of Clostridioides difficile among nursing home elders associates with a dysbiotic microbiome. Gut Microbes 2021; 13(1) doi: 10.1080/19490976.2021.1897209
|
| 63 |
Daniel E Freedberg, Hojjat Salmasian, Carol Friedman, Julian A Abrams. Proton Pump Inhibitors and Risk for Recurrent Clostridium difficile Infection Among Inpatients. American Journal of Gastroenterology 2013; 108(11): 1794 doi: 10.1038/ajg.2013.333
|
| 64 |
John F. Pohl, Raza Patel, Jeffery T. Zobell, Ellen Lin, E. Kent Korgenski, Kody Crowell, Mark W. MacKay, Aleesha Richman, Christian Larsen, Barbara A. Chatfield. Clostridium difficileInfection and Proton Pump Inhibitor Use in Hospitalized Pediatric Cystic Fibrosis Patients. Gastroenterology Research and Practice 2011; 2011: 1 doi: 10.1155/2011/345012
|
| 65 |
Grigorios I Leontiadis. Editorial : PPIs and Recurrent C. difficile Infection: No Association?. American Journal of Gastroenterology 2013; 108(11): 1802 doi: 10.1038/ajg.2013.365
|
| 66 |
Kristin M. D'Silva, Raaj Mehta, Michael Mitchell, Todd C. Lee, Vibha Singhal, Marnie Goodwin Wilson, Emily G. McDonald. Proton pump inhibitor use and risk for recurrent Clostridioides difficile infection: a systematic review and meta-analysis. Clinical Microbiology and Infection 2021; 27(5): 697 doi: 10.1016/j.cmi.2021.01.008
|
| 67 |
Preetika Sinh, Terrence A. Barrett, Laura Yun. Clostridium difficileInfection and Inflammatory Bowel Disease: A Review. Gastroenterology Research and Practice 2011; 2011: 1 doi: 10.1155/2011/136064
|
| 68 |
Courtney Hebert, Hongyan Du, Lance R. Peterson, Ari Robicsek. Electronic Health Record–Based Detection of Risk Factors for Clostridium difficile Infection Relapse. Infection Control & Hospital Epidemiology 2013; 34(4): 407 doi: 10.1086/669864
|
| 69 |
Sahil Khanna, Darrell S. Pardi. Clostridium difficile infection: management strategies for a difficult disease. Therapeutic Advances in Gastroenterology 2014; 7(2): 72 doi: 10.1177/1756283X13508519
|
| 70 |
Jose F. Garcia-Mazcorro, Jan S. Suchodolski, Katherine R. Jones, Stuart C. Clark-Price, Scot E. Dowd, Yasushi Minamoto, Melissa Markel, Jörg M. Steiner, Olivier Dossin. Effect of the proton pump inhibitor omeprazole on the gastrointestinal bacterial microbiota of healthy dogs. FEMS Microbiology Ecology 2012; 80(3): 624 doi: 10.1111/j.1574-6941.2012.01331.x
|
| 71 |
Eroboghene H. Otete, Anand S. Ahankari, Helen Jones, Kirsty J. Bolton, Caroline W. Jordan, Tim C. Boswell, Mark H. Wilcox, Neil M. Ferguson, Charles R. Beck, Richard L. Puleston, Kathryn DeRiemer. Parameters for the Mathematical Modelling of Clostridium difficile Acquisition and Transmission: A Systematic Review. PLoS ONE 2013; 8(12): e84224 doi: 10.1371/journal.pone.0084224
|
| 72 |
Palna Mehta, Ronald G Nahass, Luigi Brunetti. Acid Suppression Medications During Hospitalization as a Risk Factor for Recurrence of Clostridioides difficile Infection: Systematic Review and Meta-analysis. Clinical Infectious Diseases 2021; 73(1): e62 doi: 10.1093/cid/ciaa545
|
| 73 |
Erik R. Dubberke, Eric Schaefer, Kimberly A. Reske, Marya Zilberberg, Christopher S. Hollenbeak, Margaret A. Olsen. Attributable Inpatient Costs of RecurrentClostridium difficileInfections. Infection Control & Hospital Epidemiology 2014; 35(11): 1400 doi: 10.1086/678428
|
| 74 |
G. Goltsman, G. Gal, E. H. Mizrahi, S. Mardanov, E. Pinco, Emily Lubart. The impact of intensive staff education on rate of Clostridium difficile-associated disease in hospitalized geriatric patients. Aging Clinical and Experimental Research 2020; 32(11): 2393 doi: 10.1007/s40520-019-01424-y
|
| 75 |
Mark Safe, Wei H Chan, Steven T Leach, Lee Sutton, Kei Lui, Usha Krishnan. Widespread use of gastric acid inhibitors in infants: Are they needed? Are they safe?. World Journal of Gastrointestinal Pharmacology and Therapeutics 2016; 7(4): 531-539 doi: 10.4292/wjgpt.v7.i4.531
|
| 76 |
Hallie C. Prescott, Robert P. Dickson, Mary A. M. Rogers, Kenneth M. Langa, Theodore J. Iwashyna. Hospitalization Type and Subsequent Severe Sepsis. American Journal of Respiratory and Critical Care Medicine 2015; 192(5): 581 doi: 10.1164/rccm.201503-0483OC
|
| 77 |
Rowena Almeida, Teklu Gerbaba, Elaine O. Petrof. Recurrent Clostridium difficile infection and the microbiome. Journal of Gastroenterology 2016; 51(1): 1 doi: 10.1007/s00535-015-1099-3
|
| 78 |
A. I. Bamber, K. Fitzsimmons, J. G. Cunniffe, C. C. Beasor, C. A. Mackintosh, G. Hobbs. Diagnosis ofClostridium difficile-associated disease: examination of multiple algorithms using toxin EIA, glutamate dehydrogenase EIA and loop-mediated isothermal amplification. British Journal of Biomedical Science 2012; 69(3): 112 doi: 10.1080/09674845.2012.12069136
|
| 79 |
Ronnell Regidor. Histamine-2 receptor blockers vs proton pump inhibitors part 1: a literature review. Gastrointestinal Nursing 2013; 11(5): 30 doi: 10.12968/gasn.2013.11.5.30
|
| 80 |
Karn Wijarnpreecha, Suthanya Sornprom, Charat Thongprayoon, Parkpoom Phatharacharukul, Wisit Cheungpasitporn, Kiran Nakkala. The risk of Clostridium difficile associated diarrhea in nasogastric tube insertion: A systematic review and meta-analysis. Digestive and Liver Disease 2016; 48(5): 468 doi: 10.1016/j.dld.2016.01.012
|
| 81 |
Sailajah Janarthanan, Ivo Ditah, Douglas G Adler, Murray N Ehrinpreis. Clostridium difficile -Associated Diarrhea and Proton Pump Inhibitor Therapy: A Meta-Analysis. American Journal of Gastroenterology 2012; 107(7): 1001 doi: 10.1038/ajg.2012.179
|
| 82 |
Pandhem Samarasimha R, Michael David, Singh Manoj Y. Long term outcomes of Hospital-Identified Clostridium Difficile Infection (HICDI): A retrospective cohort analysis of adult patients in a teaching hospital. Global Journal of Medical and Clinical Case Reports 2021; : 008 doi: 10.17352/2455-5282.000118
|
| 83 |
Hideki Kumagai, Yoshihiro Shioi, Daichi Tamura, Toshiki Shitomi, Chihiro Tono. Geriatric nutritional risk index as a risk-factor for <i>Clostridioides difficile</i> infection relapse in elderly Japanese patients. Journal of Rural Medicine 2022; 17(4): 248 doi: 10.2185/jrm.2022-027
|
| 84 |
Paul Moayyedi, Grigorios I. Leontiadis. The risks of PPI therapy. Nature Reviews Gastroenterology & Hepatology 2012; 9(3): 132 doi: 10.1038/nrgastro.2011.272
|
| 85 |
Nagah Mohammed Saad, Wallaa Farouk Amin, Eman Mokhtar Shaker. Detection of toxigenic Clostridium difficile in powdered infant and follow-up formulae in Egypt. Veterinary World 2013; 6(11): 862 doi: 10.14202/vetworld.2013.862-864
|
| 86 |
Claire Nour Abou Chakra, Jacques Pepin, Stephanie Sirard, Louis Valiquette, Daniel Paredes-Sabja. Risk Factors for Recurrence, Complications and Mortality in Clostridium difficile Infection: A Systematic Review. PLoS ONE 2014; 9(6): e98400 doi: 10.1371/journal.pone.0098400
|